Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics, Inc.
“Over the last several years, we have taken strategic actions to transition the Company to focus on our neurology, orphan and specialty medicines,” said
"Assertio reflects an aspirational mindset consistent with our focus on advancing patient care. It’s a new brand identity that says we’re assertive and decisive when it comes to our mission, vision, values and strategy as well as our commitment to delivering shareholder value. It’s forward thinking and confident, energetic and entrepreneurial. It’s a new name – and a renewed mission to advance patient care in our core areas of neurology, orphan and specialty medicines.”
Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Company’s core areas of neurology, orphan and specialty medicines. Assertio currently markets three
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks related to our corporate name change, our reincorporation in
INVESTOR AND MEDIA CONTACTS:
SVP, Investor Relations and Corporate Communications
Source: Assertio Therapeutics, Inc.
Minimum 15 minutes delayed.